Fig. 2
From: Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
Efficacy of fremanezumab in all patients. a Changes in MMD, MHD, AMD, and NRS from baseline. *Significant difference compared with baseline. * adjusted p < 0.05; **adjusted p < 0.01; ***adjusted p < 0.001. Error bars represent 95% confidence interval. Abbreviations: MMD, monthly migraine days; MHD, monthly headache days; AMD, monthly days with acute medication use; NRS, numerical rating scale; 1 M, 1 month; 2 M; 2 months; 3 M; 3 months; 4 M, 4 months. b Responder rates. Proportion of patients with responder rates of 25%, 50%, 75%, and 100%. Abbreviations: 1 M, 1 month; 2 M, 2 months; 3 M, 3 months; 4 M, 4 months; RR, responder rate